LCTX News & Events

Lineage Cell Therapeutics (LCTX) announced that 36-month results from patients enrolled in a Phase 1/2a clinical study of RG6501 in patients with geographic atrophy secondary to age-related macular degeneration, were presented at the Foundation Fighting Blindness' Retinal Therapeutics Innovation Summit 2026. The presentation, "Retinal Pigment Epithelium Cell Therapy in Geographic Atrophy Secondary to Age-related Macular Degeneration: 3 Year Results from the Phase 1/2a Study," was presented by Eyal Banin, M.D., Ph.D., Center for Retinal and Macular Degenerations, Department of Ophthalmology Hadassah-Hebrew University Medical Center and Faculty of Medicine, on behalf of Roche and Genentech, a member of the Roche (RHHBY). Key highlights: Gains in best corrected visual acuity of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy lesion site; OCT imaging indicated partial restoration of outer retinal structure, re-appearance of an RPE layer, and features associated with recovery of photoreceptors; Anatomical and functional improvements occur following a single administration of OpRegen cell therapy

Lineage Cell Therapeutics announced the formation of a Scientific Advisory Board, SAB, to provide strategic counsel and insights into the development of Lineage's novel cell transplant pipeline, built on the Company's proprietary cell differentiation and expansion platform, AlloSCOPE. The founding member of the SAB is Joachim Fruebis, Ph.D. Additional SAB members are expected to be added throughout the remainder of the year.